Subscribe
shutterstock_1106804450_penpics_studio
PENpics Studio / Shutterstock.com
5 August 2021GenericsSophie Topham

UK experimental use exemptions: Part 3—the expanded exemption

In the third article of a four-part series on experimental use exemptions from infringement in the UK, we consider the expansion of the original experimental use exemption (Section 60(5)(b) UK Patents Act [UKPA] 1977) introduced by the Legislative Reform (Patents) Order 2014/1997.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
UK experimental use exemptions: part 1—the original
15 July 2021   In the first of a four-part series, Sophie Topham of Marks & Clerk explores how experimental use provides life sciences products with essential relief from patent infringement
Generics
UK experimental use exemptions: Part 2—the Bolar exemption
22 July 2021   In the second of a four-part series, Sophie Topham of Marks & Clerk explains the rules around the exemption for studies, tests, and trials required for generic and biosimilar medicines.
Europe
UK experimental use exemptions: Part 4—the SPC manufacturing and stockpiling waiver
10 August 2021   In the final article of a four-part series, Sophie Topham of Marks & Clerk discusses the supplementary protection certificate manufacturing waiver.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

More on this story

Europe
UK experimental use exemptions: Part 4—the SPC manufacturing and stockpiling waiver
10 August 2021   In the final article of a four-part series, Sophie Topham of Marks & Clerk discusses the supplementary protection certificate manufacturing waiver.
Big Pharma
UK experimental use exemptions: part 1—the original
15 July 2021   In the first of a four-part series, Sophie Topham of Marks & Clerk explores how experimental use provides life sciences products with essential relief from patent infringement
Generics
UK experimental use exemptions: Part 2—the Bolar exemption
22 July 2021   In the second of a four-part series, Sophie Topham of Marks & Clerk explains the rules around the exemption for studies, tests, and trials required for generic and biosimilar medicines.

More on this story

Europe
UK experimental use exemptions: Part 4—the SPC manufacturing and stockpiling waiver
10 August 2021   In the final article of a four-part series, Sophie Topham of Marks & Clerk discusses the supplementary protection certificate manufacturing waiver.
Big Pharma
UK experimental use exemptions: part 1—the original
15 July 2021   In the first of a four-part series, Sophie Topham of Marks & Clerk explores how experimental use provides life sciences products with essential relief from patent infringement
Generics
UK experimental use exemptions: Part 2—the Bolar exemption
22 July 2021   In the second of a four-part series, Sophie Topham of Marks & Clerk explains the rules around the exemption for studies, tests, and trials required for generic and biosimilar medicines.

More features

White & Case hires experienced litigator from A&O Shearman
China’s new policies on foreign investment in healthcare and biotech
Startup CFO’s betrayal is a lesson in preparing for the worst
Sandoz lands reduced antitrust award of $70m
Apple wins just $250 in Masimo smartwatch clash
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
MSN scores win in battle with Novartis over heart drug generic
How post-filing data rescued Novo Nordisk’s Ozempic patent in China